A comparative effectiveness study examined clinical outcomes and costs after treatment with a febrile neutropenia therapy vs a biosimilar for patients with non-myeloid cancer undergoing chemotherapy.
Inadequate response to targeted immunomodulators for rheumatoid arthritis may lead to significantly higher economic burden, including higher health care resource utilization.
A recent study analyzed the effects of implementing a clinical pathway for thyroid cancer in a hospital setting.
A JAMA Oncology research letter sheds light on the average additional costs associated with CAR-T therapy, which can be from $30,000 to $36,000 per patient.
Adam M Brufsky, MD, PhD, discusses some of the key topics and data for examining the clinical and cost implications of HER-positive breast cancer care in the value-based care era.
A new economic model may help clinicians and payers have a better understanding of the relative clinical benefits and costs of second-line treatment options for metastatic renal cell carcinoma.
A recent study found that providing treatment in what setting may help improve overall survival in adolescent and young adult patients with acute lymphoblastic leukemia?
Allen Lichter, MD, FASCO, delves into the growing concern of financial toxicity among stakeholders in the cancer community and the efforts of the Value in Cancer Care Consortium to improve the access, affordability, and value of cancer therapies.
A recent study found that diagnosis-to-treatment interval may be linked with prognostic clinical factors and event-free survival in newly diagnosed diffuse large B-cell lymphoma.
According to a presentation at the SGO Annual Meeting, which adverse event associated with PARP inhibitor administration should be a top concern for oncologists?